6505--Melatonin Tablets Effective 09/15/26 - 09/14/27
Overview
Buyer
Place of Performance
NAICS
PSC
Set Aside
Original Source
Timeline
Qualification Details
Fit reasons
- NAICS alignment with historical contract wins in similar service areas.
- Scope strongly matches core technical capabilities and delivery model.
Risks
- Past performance thresholds may require one additional teaming partner.
- Potential clarification needed on staffing minimums before bid/no-bid.
Next steps
Validate eligibility requirements, assign capture owner, and schedule partner outreach to confirm teaming strategy before submission planning.
Quick Summary
The Department of Veterans Affairs (VA) has awarded a Firm Fixed-Price, Indefinite-Delivery Requirements contract for Melatonin Tablets to MARLEX PHARMACEUTICALS INC, valued at $5,939,023.25. This award, under solicitation 36E79726R0015, ensures the supply of Melatonin to the VA, Department of Defense (DoD), Bureau of Prisons (BOP), Indian Health Service (IHS), and Federal Health Care Center (FHCC). The contract's period of performance is from September 15, 2026, to September 14, 2027.
Scope of Work
This contract covers the supply of Melatonin in 1mg, 3mg, and 5mg strengths, in capsule or tablet form. Key requirements included unit of use packaging with child-proof closures, a minimum bottle volume of 120cc, and specific label dimensions (5.25" x 2"). Glass bottles were not acceptable. Offerors were required to provide an 11-digit National Drug Code (NDC) unique to their company for each drug and ensure products met FDA cGMP standards.
Contract Details
- Awardee: MARLEX PHARMACEUTICALS INC (UEI: VSSNJEFMPLB3)
- Award Value: $5,939,023.25
- Contract Type: Firm Fixed Price, Indefinite-Delivery Requirements
- Period of Performance: September 15, 2026 – September 14, 2027 (Base Year)
- Option Periods: The original solicitation included one base year plus four one-year option periods.
- Set-Aside: Unrestricted
- Solicitation Number: 36E79726R0015
- Product Service Code (PSC): 6505 (Drugs And Biologicals)
Solicitation & Evaluation
The solicitation, issued by the VA's National Acquisition Center, sought a single aggregate award for all line items. Evaluation was based on the lowest price technically acceptable offer, requiring offerors to submit product samples (without product) by the due date. The original offer due date of March 26, 2026, was extended to April 9, 2026, at 2:30 PM CT via amendment. Technical acceptability included meeting product specifications, NDC/UPC uniqueness, and cGMP compliance.
Additional Notes
Contract items will be distributed through the VA’s and DoD’s Pharmaceutical Prime Vendor (PPV) Programs. The Contracting Officer for this award is Deb Fassl (Deborah.Fassl@va.gov, 708-786-5894).